Systematic protein- and peptide-analysis in cerebrospinal fluid of patients with central nervous system lymphoma and glioblastoma multiforme

• Antragstellerin: Privatdozentin Dr. Beate Gleißner
• Fachliche Zuordnung: Hämatologie, Onkologie
• Förderung: Förderung von 2007 bis 2009
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 26477726

The most frequent primary brain tumors in adults are glioblastoma multiforme (GBM) for which primary central nervous system lymphoma (PCNSL) represents the most important differential diagnosis. In contrast to GBM, extensive surgical resection is avoided in PCNSL patients as they respond to systemic chemotherapy and radiotherapy. Up to now tissue diagnosis by stereotactic biopsy is required as malignant cells can be unequivocally detected in the cerebrospinal fluid (CSF) only in 10% of the PCNSL and GBM patients. This study aims to identify disease specific proteins and peptides in CSF supernatants from PCNSL patients, patients with glioblastomas, and controls. The CSF proteins will be profiled by nano-liquid chromatography (nano-LC) coupled to MALDI MS. Nano-LC-MALDI MS allows detection of a large number of proteins and peptides in complex mixtures, from minute amounts of starting material. By fragment ion analysis (MS/MS) proteins can be identified by database searching. The determined protein- and peptide- profiles will be compared for patients with and without meningeal dissemination of PCNSL or GBM, and a control population (patients with hydrocephalus internus and patients with normal CSF) to exclude nonspecific CSF protein changes and shifts due to a disruption of the blood-brain barrier. The aim of the analysis is to determine disease specific CSF protein pattern and to enlarge the diagnostic armentarium for patients with high-grade primary brain tumors to circumvent at best surgical intervention in selected patients and enable early diagnosis.

• DFG-Verfahren: Sachbeihilfen
• Internationaler Bezug: Schweiz